(Q34984108)

5 August 2017

1 reference

title

Treatment of patients with hepatitis C and normal serum aminotransferase levels (English)

1 reference

5 August 2017

1 reference

Bruce R Bacon

1

1 reference

PubMed ID

12407592

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

36

1 reference

5 August 2017

5 Suppl 1

1 reference

5 August 2017

S179-84

1 reference

Therapy of hepatitis C: patients with normal aminotransferase levels

5 August 2017

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Transmission of hepatitis C virus by a cardiac surgeon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Hepatitis C and progression of HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Risk of hepatitis C seroconversion after occupational exposures in health care workers*1

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

Mother-to-infant transmission of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.36386

21 January 2018

Identifiers

DOI

10.1053/JHEP.2002.36386

1 reference

5 August 2017

1 reference

PubMed ID

12407592